Assessment of durable remission and relapse-free survival of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells (CTL119) in CAR-naive and CAR-exposed children and young adults with relapsed/refractory acute lymphoblastic leukemia: A phase I study

Trial Profile

Assessment of durable remission and relapse-free survival of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells (CTL119) in CAR-naive and CAR-exposed children and young adults with relapsed/refractory acute lymphoblastic leukemia: A phase I study

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Dec 2017

At a glance

  • Drugs CTL 119 (Primary)
  • Indications Acute lymphoblastic leukaemia; B-cell leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 22 Dec 2017 New trial record
    • 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top